November 2016 in “Therapeutic Delivery” New drugs for Alzheimer's and rheumatoid arthritis advanced, a Zika vaccine is in development, and there were business deals in anesthesia and oncology.
8 citations
,
January 2023 in “Journal of Research in Pharmacy” Compounds from turmeric and bitter show strong potential as antiviral agents against the influenza A virus.
156 citations
,
August 2014 in “Cochrane library” Budesonide is not effective for maintaining remission in Crohn's disease beyond three months.
142 citations
,
November 2009 in “BMC Complementary and Alternative Medicine” Tridax procumbens significantly lowers blood sugar in diabetic rats.
Early NAS level changes affect alcohol consumption vulnerability.
9 citations
,
March 2018 in “International journal of molecular sciences” Allopregnanolone changes gene expression in glioblastoma cells.
45 citations
,
July 2025 in “Journal of Medicinal Chemistry” Vepdegestrant may become the first FDA-approved PROTAC degrader, marking a new era in drug development.
47 citations
,
April 2017 in “European Journal of Pharmaceutics and Biopharmaceutics” The new dutasteride formula can be applied to the skin, may promote hair growth, and has fewer side effects.
October 2025 in “International Journal of Dermatology” GLP-1 receptor agonists may cause hair loss, but regrowth is rare.
6 citations
,
November 2019 in “Journal of Cosmetic Dermatology” The compound improved hair growth and reduced hair loss.
June 2017 in “DOAJ (DOAJ: Directory of Open Access Journals)” Combining finasteride with dimethyl-β-cyclodextrin improves its absorption and bioavailability.
January 2025 in “International Journal for Research Trends and Innovation” The polyherbal hair oil promotes hair growth effectively and is safe for use.
March 2025 in “NATIONS UNIVERSITY INTERNATIONAL JOURNAL OF MULTI-DISCIPLINARY STUDIES” Baricitinib effectively improved skin and hair conditions in a patient with alopecia areata and atopic dermatitis.
5 citations
,
March 2017 in “Natural Product Research” Researchers found eight natural compounds and essential oils in the Italian plant Bituminaria basaltica, which are typical for its genus and known for bioactivity.
19 citations
,
July 2005 in “Steroids” Testosterone increases 3α-androstanediol levels, which can be blocked by finasteride.
October 2007 in “European Neuropsychopharmacology”
25 citations
,
April 2014 in “Journal of Scientific and Innovative Research” Tridax procumbens may help treat diabetes.
June 2024 in “Korean Journal of Pharmacognosy” The compound from Rhododendron mucronulatum roots may help treat male pattern hair loss.
Hair RiseTM microemulsion effectively promotes hair growth and treats hair loss better than standard treatments.
Lipid carriers improve delivery of hair loss treatments to follicles.
September 2025 in “Cureus” GLP-1 receptor agonists may cause hair loss, but more research is needed.
1 citations
,
June 2022 in “JAMA” Baricitinib, a medication taken by mouth, was effective in regrowing hair for people with severe hair loss.
10 citations
,
March 2023 in “Journal of Chemistry” New compounds show promise for treating benign prostate hyperplasia with fewer side effects.
February 2023 in “Reactions Weekly” March 2023 in “Epilepsia” Trilostane may help delay epilepsy development by increasing certain brain chemicals.
2 citations
,
January 2011 in “Andrologia” Flutamide and a new synthetic steroid affected brain and prostate chemicals and showed potential for treating androgen-related conditions and epilepsy.
110 citations
,
August 2015 in “Neuropsychopharmacology” High-dose dutasteride reduces PMDD symptoms by stabilizing neurosteroid levels.
59 citations
,
January 2015 in “Nanoscale” The new micelle formulation delivers acne treatment more effectively and safely than current gels.
June 2010 in “Journal of Chemical Crystallography” The compound was successfully made and shows potential for treating prostate cancer.
82 citations
,
February 1989 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” A three-month treatment with a GnRH agonist significantly lowered androgen levels and 5α-reductase activity in men with benign prostatic hyperplasia.